Loading...

AptarGroup, Inc.

ATRNYSE
Healthcare
Medical - Instruments & Supplies
$139.43
$-1.21(-0.86%)

AptarGroup, Inc. (ATR) Financial Performance & Income Statement Overview

Review AptarGroup, Inc. (ATR) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
2.74%
2.74%
Operating Income Growth
22.89%
22.89%
Net Income Growth
31.65%
31.65%
Operating Cash Flow Growth
11.85%
11.85%
Operating Margin
14.34%
14.34%
Gross Margin
36.38%
36.38%
Net Profit Margin
10.84%
10.84%
ROE
15.28%
15.28%
ROIC
14.81%
14.81%

AptarGroup, Inc. (ATR) Income Statement & Financial Overview

Access detailed annual and quarterly income data for AptarGroup, Inc. ATR financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$887.30M$848.09M$909.29M$910.06M
Cost of Revenue$550.89M$518.67M$558.51M$567.44M
Gross Profit$336.41M$329.41M$350.78M$342.62M
Gross Profit Ratio$0.38$0.39$0.39$0.38
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$155.28M$138.51M$141.60M$149.33M
Operating Expenses$222.97M$209.31M$212.48M$216.61M
Total Costs & Expenses$773.86M$727.98M$770.99M$784.05M
Interest Income$2.81M$3.08M$3.02M$3.10M
Interest Expense$11.35M$11.37M$12.29M$10.06M
Depreciation & Amortization$65.65M$67.45M$67.02M$64.97M
EBITDA$183.01M$194.89M$210.44M$193.28M
EBITDA Ratio$0.21$0.23$0.23$0.21
Operating Income$113.45M$120.11M$138.30M$126.01M
Operating Income Ratio$0.13$0.14$0.15$0.14
Other Income/Expenses (Net)-$7.43M-$4.04M-$7.17M-$7.76M
Income Before Tax$106.02M$116.07M$131.13M$118.25M
Income Before Tax Ratio$0.12$0.14$0.14$0.13
Income Tax Expense$27.35M$15.21M$31.21M$27.79M
Net Income$78.80M$100.94M$100.04M$90.45M
Net Income Ratio$0.09$0.12$0.11$0.10
EPS$1.19$1.52$1.51$1.36
Diluted EPS$1.17$1.49$1.48$1.34
Weighted Avg Shares Outstanding$66.27M$66.51M$66.44M$66.31M
Weighted Avg Shares Outstanding (Diluted)$67.49M$67.92M$67.72M$67.58M

The company's financials show resilient growth, with revenue advancing from $910.06M in Q2 2024 to $887.30M in Q1 2025. Gross profit remained healthy with margins at 38% in Q1 2025 compared to 38% in Q2 2024. Operating income hit $113.45M last quarter, sustaining a consistent 13% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $183.01M. Net income dropped to $78.80M, while earnings per share reached $1.19. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;